Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
[en] Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal chromosomal aberrations in Philadelphia-negative (Ph-) cells during treatment has been reported. We describe two CML patients in chronic phase who presented with complete cytogenetic responses during imatinib mesylate therapy but developed new clonal chromosomal rearrangements in Ph- cells. The first patient presented with a duplication of chromosome 1, dup(1)(q21q42), and the second showed two new clonal aberrations consisting of inv(1)(q12q32) and del(7)(q22) in the same clone.
Disciplines :
Genetics & genetic processes
Author, co-author :
Herens, Christian ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Croisiau, Christiane
Tassin, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Bours, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Language :
English
Title :
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Publication date :
2003
Journal title :
Cancer Genetics and Cytogenetics
ISSN :
0165-4608
eISSN :
1873-4456
Publisher :
Elsevier Science, New York, United States - New York
Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 43:1973;290-293.
Sawyers C.L. Chronic myeloid leukemia. N Engl J Med. 340:1999;1330-1340.
Druker B.J., Talpaz M., Resta D.J., Bin Peng R.N., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
Marktel S., Bua M., Marin D., Chase A., Udom C., Armstrong L., Apperley J.F., Olavarria E., Goldman J.M. Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. [abstract] Blood. 98:2001;617a.
Gambacorti-Passeri C., Giudici G., Le Coutre P., Bungaro S., Pogliani E.M., Kreuzer K.-A., Tornaghi L., Alberti D., Corneo G., Biondi A. Nonrandom chromosomal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic responses (MCR) with STI571 (Gleevec™). [abstract] Blood. 98:2001;257b.
Meunier V., Giraudier S., Van den Akker J., Perot C., Jouault H., Caron-Servan B., Robin V., Tulliez M., Imbert M. Treatment with STI571 (Novartis) in chronic myeloid leukemia (CML): unexpected hematological findings in a series of 26 patients. [abstract] Blood. 98:2001;263b.
Andersen M.K., Pedersen-Bjergaard, Kjeldsen L., Dufva I.H., Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 16:2002;1390-1395. [letter].
Casali M., Truglio F., Milone G., Raimondo F., Parrinello G., Maserati E., Pasquali F. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer. 4:1992;269-270.
Bilhou-Nabera C., Marit G., Devianne I., Viard F., Salzes S., Montastruc M., Renoux M., Broustet A., Reiffers J., Bernard P. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer. 4:1993;255-256.
Ariyama T., Inazawa J., Uemura Y., Kakazu N., Maekawa T., Urase F., Irimajiri K., Horiuchi A., Nakamura Y., Abe T. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet. 81:1995;20-23.
Ohtsuka E., Kikuchi H., Abe Y., Moriyama K., Ohno E., Hirota K., Tezono K., Nasu M. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome. Br J Cancer. 90:1995;951-953.
Izumi T., Imagawa S., Hatake K., Miura Y., Ariyama T., Inazawa J., Abe T. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Int J Hematol. 64:1996;73-77.
Fayad L., Kantarjian H., O'Brien S., Seong D., Albitar M., Keating M., Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 11:1997;767-771.
